Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. 2002

Hirotaka Osada, and Yoshio Tatematsu, and Yasushi Yatabe, and Taku Nakagawa, and Hiroyuki Konishi, and Tomoko Harano, and Ekmel Tezel, and Minoru Takada, and Takashi Takahashi
Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan. hosada@aichi-cc.jp

One isoform of the 14-3-3 family, 14-3-3sigma, plays a crucial role in the G2 checkpoint by sequestering Cdc2-cyclinB1 in the cytoplasm, and the expression of 14-3-3sigma is frequently lost in breast cancers. This loss of expression is thought to cause a G2 checkpoint defect, resulting in chromosomal aberrations. Since lung cancers frequently carry numerous chromosomal aberrations, we examined the DNA methylation status and expression level of the 14-3-3sigma gene in 37 lung cancer cell lines and 30 primary lung tumor specimens. We found that small cell lung cancer (SCLC) cell lines frequently showed DNA hypermethylation (9 of 13 lines, 69%), and subsequent silencing of the 14-3-3sigma gene. Among non-small cell lung cancers (NSCLC), large cell lung cancer cell lines showed frequent hypermethylation and silencing of 14-3-3sigma (4 or 7 lines, 57%). In contrast, in other NSCLC cell lines, hypermethylation occurred very rarely (1 of 17 lines, 6%). All eight primary SCLC specimens examined also showed a loss or significant reduction in 14-3-3sigma expression in vivo, while a loss or reduction of 14-3-3sigma expression was very rare in primary NSCLC specimens (1 of 22 tissues, 5%). This is the first description that indicates lung cancers frequently show significant inactivation of the 14-3-3sigma gene mainly due to DNA hypermethylation in SCLC, but rarely in NSCLC, suggesting involvement of the 14-3-3sigma gene in lung tumorigenesis in a histological type-specific manner.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005092 Exonucleases Enzymes that catalyze the release of mononucleotides by the hydrolysis of the terminal bond of deoxyribonucleotide or ribonucleotide chains. Exonuclease,3'-5'-Exonuclease,3'-5'-Exonucleases,5'-3'-Exonuclease,5'-3'-Exonucleases,3' 5' Exonuclease,3' 5' Exonucleases,5' 3' Exonuclease,5' 3' Exonucleases
D005095 Exoribonucleases A family of enzymes that catalyze the exonucleolytic cleavage of RNA. It includes EC 3.1.13.-, EC 3.1.14.-, EC 3.1.15.-, and EC 3.1.16.-. EC 3.1.- Exoribonuclease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012334 RNA, Neoplasm RNA present in neoplastic tissue. Neoplasm RNA
D014176 Protein Biosynthesis The biosynthesis of PEPTIDES and PROTEINS on RIBOSOMES, directed by MESSENGER RNA, via TRANSFER RNA that is charged with standard proteinogenic AMINO ACIDS. Genetic Translation,Peptide Biosynthesis, Ribosomal,Protein Translation,Translation, Genetic,Protein Biosynthesis, Ribosomal,Protein Synthesis, Ribosomal,Ribosomal Peptide Biosynthesis,mRNA Translation,Biosynthesis, Protein,Biosynthesis, Ribosomal Peptide,Biosynthesis, Ribosomal Protein,Genetic Translations,Ribosomal Protein Biosynthesis,Ribosomal Protein Synthesis,Synthesis, Ribosomal Protein,Translation, Protein,Translation, mRNA,mRNA Translations

Related Publications

Hirotaka Osada, and Yoshio Tatematsu, and Yasushi Yatabe, and Taku Nakagawa, and Hiroyuki Konishi, and Tomoko Harano, and Ekmel Tezel, and Minoru Takada, and Takashi Takahashi
June 2006, Seminars in cancer biology,
Hirotaka Osada, and Yoshio Tatematsu, and Yasushi Yatabe, and Taku Nakagawa, and Hiroyuki Konishi, and Tomoko Harano, and Ekmel Tezel, and Minoru Takada, and Takashi Takahashi
June 2009, American journal of translational research,
Hirotaka Osada, and Yoshio Tatematsu, and Yasushi Yatabe, and Taku Nakagawa, and Hiroyuki Konishi, and Tomoko Harano, and Ekmel Tezel, and Minoru Takada, and Takashi Takahashi
April 2005, Cell research,
Hirotaka Osada, and Yoshio Tatematsu, and Yasushi Yatabe, and Taku Nakagawa, and Hiroyuki Konishi, and Tomoko Harano, and Ekmel Tezel, and Minoru Takada, and Takashi Takahashi
September 2005, Neoplasia (New York, N.Y.),
Hirotaka Osada, and Yoshio Tatematsu, and Yasushi Yatabe, and Taku Nakagawa, and Hiroyuki Konishi, and Tomoko Harano, and Ekmel Tezel, and Minoru Takada, and Takashi Takahashi
October 2000, Molecular and cellular biology,
Hirotaka Osada, and Yoshio Tatematsu, and Yasushi Yatabe, and Taku Nakagawa, and Hiroyuki Konishi, and Tomoko Harano, and Ekmel Tezel, and Minoru Takada, and Takashi Takahashi
July 2004, Biochemical and biophysical research communications,
Hirotaka Osada, and Yoshio Tatematsu, and Yasushi Yatabe, and Taku Nakagawa, and Hiroyuki Konishi, and Tomoko Harano, and Ekmel Tezel, and Minoru Takada, and Takashi Takahashi
August 2006, Biochemical and biophysical research communications,
Hirotaka Osada, and Yoshio Tatematsu, and Yasushi Yatabe, and Taku Nakagawa, and Hiroyuki Konishi, and Tomoko Harano, and Ekmel Tezel, and Minoru Takada, and Takashi Takahashi
March 2002, Oncogene,
Hirotaka Osada, and Yoshio Tatematsu, and Yasushi Yatabe, and Taku Nakagawa, and Hiroyuki Konishi, and Tomoko Harano, and Ekmel Tezel, and Minoru Takada, and Takashi Takahashi
June 2006, Seminars in cancer biology,
Hirotaka Osada, and Yoshio Tatematsu, and Yasushi Yatabe, and Taku Nakagawa, and Hiroyuki Konishi, and Tomoko Harano, and Ekmel Tezel, and Minoru Takada, and Takashi Takahashi
June 2009, Anticancer research,
Copied contents to your clipboard!